Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aurum Pharmaceuticals
Romford, Essex, United Kingdomaurumgroup.org.uk ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Aurum Pharmaceuticals, via its division Aurum Biosciences, has advanced its lead program ABL-101 (perfluorocarbon oxygen carrier) to Phase 2 clinical trials for acute ischemic stroke and has ongoing projects for heart disease, cancer, epilepsy, dementia, with early clinical validation showing potential for tissue protection and diagnostics in stroke and spinal cord injury.
- Therapeutic areas
- OncologyNeurologyImmunologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Aurum Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurum Pharmaceuticals.